UnknownNot Applicable

Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR)

1,000 participantsStarted 2024-05-01

Plain-language summary

The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are: * Do patients with AIP have higher incidence of cancer in comparison to general population? * What is the overall prevalence of cancer in AIP patients? * What are the characteristics of AIP patients associated with the incidence of cancer?

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with AIP after 2005, including type 1, type 2, and not-otherwise-specified (NOS) AIP, regardless of the diagnostic criteria used. Exclusion Criteria: * Patients younger than 18 years at last contact * Patients with less than 12 months of follow up after diagnosis * Patients with immune checkpoint inhibitor-induced pancreatitis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Standardized incidence ratio (SIR) of first invasive cancer

Timeframe: up to 20 years

Trial details

NCT IDNCT06328101

SponsorUniversity Medical Center Goettingen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-01

Contact for this trial

Sara Nikolić, MD

+38651261676 s.nikolic91@gmail.com

View on ClinicalTrials.gov More Autoimmune Pancreatitis Type 1 trials